Syneos Health, Inc. SYNH
Day range unavailable
52-week range unavailable
- Market cap
- 4.39B
- Revenue (ttm)
- 5.41B
- Profit margin
- 2.74%
- Shares out
- 103.71M
- Forward P/E
- 10.77
- Beta
- 1.59
- Analysts
- Hold
- Price target
- 42.56 (-1.0%)
- Earnings date
- Nov 2, 2023
Key statistics
- Enterprise value
- 7.15B
- PEG ratio
- 41.30
- Price / sales
- 0.81
- Price / book
- 1.27
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 1.50%
- Free cash flow
- 302.27M
- Total cash
- 116.02M
- Total debt
- 2.89B
- Return on equity
- 4.39%
- Short % of float
- 4.94%
- 50-day average
- 41.41
- 200-day average
- 39.14
Analyst view
Consensus: hold
- Target (low)
- 40.00
- Target (mean)
- 42.56
- Target (high)
- 43.00
- Strong buy1
- Buy0
- Hold12
- Sell0
- Strong sell0
Next earnings
Nov 2, 2023
Expected Nov 2, 2023. Consensus EPS estimate 0.79.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 2, 2023 | Sep 1, 2023 | 0.81 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.78 | — | — | — |
| May 10, 2023 | Mar 1, 2023 | 0.67 | — | — | — |
| Feb 16, 2023 | Dec 1, 2022 | 1.18 | — | — | — |
| Nov 3, 2022 | Sep 1, 2022 | 1.32 | — | — | — |
| Aug 2, 2022 | Jun 1, 2022 | 1.20 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 16, 2023 | Mizuho | main | Neutral | Neutral |
| May 11, 2023 | Baird | down | Outperform | Neutral |
| May 11, 2023 | Deutsche Bank | down | Buy | Hold |
| May 11, 2023 | Barclays | up | Underweight | Equal-Weight |
| Apr 4, 2023 | Barclays | main | — | Underweight |
| Mar 1, 2023 | Barclays | main | — | Underweight |
About Syneos Health, Inc.
Syneos Health, Inc., operates as an integrated biopharmaceutical solutions company. The company operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in Phase I to IV of clinical development. This segment offers individual services, including regulatory consulting, project management, protocol development, investigational site recruitment, clinical monitoring, technology-enabled patient recruitment and engagement, clinical home health services, clinical trial diversity, biometrics, and regulatory affairs. The Commercial Solutions segment provides commercialization services, including deployment solutions, communications solutions, such as public relations, advertising, and medical communication; and consulting services. Its customers include companies in the biopharmaceutical, biotechnology, and medical device industries. It operates in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company has a strategic partnership with uMotif Limited to deliver patient-centric eClinical platform. The company was formerly known as INC Research Holdings, Inc. and changed its name to Syneos Health, Inc. in January 2018. Syneos Health, Inc. was incorporated in 2010 and is headquartered in Morrisville, North Carolina.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Country
- United States
- Website
- syneoshealth.com
News
Syneos Health Appoints Greg Licholai as Chief Medical Officer to Advance Next-Generation Drug Development 
causaLens Expands Strategic Partnership with Syneos Health to Scale Agentic AI in Biopharma Commercialization 
KAI Conversations Announces Strategic Partnership with Syneos Health to Advance U.S. Pharmaceutical Commercialization 
Syneos Health Appoints Simon Bartle as Chief Human Resources Officer 
Real World Evidence (RWE) Oncology Market to Reach $3.51 Billion by 2035, Growing at a CAGR of 14.7% from 2025--Exclusive Report by Meticulous Research® 
SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization 
Syneos Health Appoints Costa Panagos as Chief Executive Officer 
Crossject engages Syneos Health for U.S. commercial launch of ZEPIZURE® 
Elligo Health Research Announces Expansion of Study Marketplace With Syneos Health 
Syneos Health Closes Transaction with Private Investment Firms
Your note
Sign in to keep a note on SYNH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BODEM BARBARA W | Director | Stock Award(Grant) | May 24, 2023 | 8,385 |
| CONNAUGHTON BERNADETTE M. | Director | Stock Award(Grant) | May 24, 2023 | 14,778 |
| DINEEN JOHN M | Director | Stock Award(Grant) | May 24, 2023 | 27,492 |
| KLITGAARD WILLIAM E | Director | Stock Award(Grant) | May 24, 2023 | 7,370 |
| MEGGS JASON M | Chief Financial Officer | Stock Award(Grant) | Feb 22, 2023 | 71,112 |
| MEYERS KENNETH F. | Director | Stock Award(Grant) | May 24, 2023 | 25,010 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 10.14% | 10,505,743 | 444.71M | Mar 30, 2023 |
| Vanguard Group, Inc. (The) | 10.08% | 10,449,163 | 442.31M | Mar 30, 2023 |
| Wellington Management Group, LLP | 7.25% | 7,509,348 | 317.87M | Mar 30, 2023 |
| ClearBridge Investments, LLC | 4.00% | 4,148,928 | 175.62M | Mar 30, 2023 |
| Shaw D.E. & Co., Inc. | 3.16% | 3,279,774 | 138.83M | Mar 30, 2023 |
| Barclays Plc | 2.95% | 3,060,494 | 129.55M | Mar 30, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Midcap ETF | 3.11% | 3,206,161 | 135.72M | Feb 27, 2023 |
| Vanguard Total Stock Market Index Fund | 3.02% | 3,120,123 | 132.07M | Dec 30, 2022 |
| Vanguard Small-Cap Index Fund | 2.57% | 2,651,122 | 112.22M | Dec 30, 2022 |
| Vanguard Specialized-Health Care Fund | 1.85% | 1,911,256 | 80.90M | Jan 30, 2023 |
| Vanguard Small Cap Value Index Fund | 1.80% | 1,857,891 | 78.64M | Dec 30, 2022 |
| Legg Mason Clearbridge Small Cap Growth Fd | 1.42% | 1,463,663 | 61.96M | Jan 30, 2023 |